Semaglutide works by mimicking a hormone called glucagon-like peptide-1 (GLP-1). This hormone is secreted in the gut and targets areas of the brain that regulate appetite and satiety (sense of fullness after eating). In 2017, it was released as an anti-diabetic medication used to treat type 2 diabetes under the name Ozempic. In June 2021, it was approved for "chronic weight management" in obese individuals with a BMI ≥ 30 or overweight BMI ≥ 27 with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol. It was released under the brand name Wegovy.
Unfortunately, medications used to treat obesity are not usually covered by insurance and the cost of Wegovy is a staggering $1300-1400 per month. There is also currently a nationwide shortage of Wegovy so Health Care Providers have been advised by the manufacturer to not place any new patients on Wegovy. The manufacturer has also stopped advertising and promoting it.
Semaglutide treatment is a once a week subcutaneous (SQ) injection which is typically injected into the abdominal fat. SQ injections are VERY easy to do and usually painless! Most patients learn how to do this during the first visit!
1) Schedule your FREE 15 min phone consultation
2) Labs may be required if not done within the past 12 months. After phone consult, schedule your initial in-office visit.
3) One week follow up to receive your medication and how to administer it
4) Two week follow up to review how to draw up and administer injection (if needed).
5) Follow-up office visit, telemed, or phone call every 4 weeks
5) Labs and in-office visit every 3 months
The most common side effects of semaglutide are gastrointestinal, and include:
Other more serious side effects include:
If you experience any serious side effects, contact your healthcare provider immediately or seek emergency treatment.
The medication should not be used in anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN 2), because there is an increased risk of developing thyroid C-cell tumors. You are NOT a good candidate for semaglutide if you currently have or have had in the past any of the following: diabetic retinopathy, low blood sugar (hypoglycemia), poor kidney function, or pancreatitis,
There is also an increased risk of other complications including:
Not everyone will respond to semaglutide—about 13% of individuals with obesity in the semaglutide clinical trials didn’t lose any weight. Researchers say this is because there are different kinds—or subtypes—of obesity that remain unknown.
This is an excellent video that demonstrates step-by-step exactly how to draw up and inject medication subcutaneously. Highly recommended and the New Zealand accent makes it fun!
Sign up to hear from us and receive special offers!
Alpha Health & Wellness
Located inside A Suite Salon, 1043 S State Rd 7, Suite 121, Wellington FL, 33414
Copyright © 2022 Alpha Health & Wellness - All Rights Reserved.
Powered by GoDaddy